Scarica l'app Stockscreener
2.40
3.61%
-0.09
Precedente Chiudi:
$2.49
Aprire:
$2.48
Volume 24 ore:
346.65K
Relative Volume:
1.06
Capitalizzazione di mercato:
$39.01M
Reddito:
-
Utile/perdita netta:
$-64.47M
Rapporto P/E:
-0.388
EPS:
-6.1852
Flusso di cassa netto:
$-52.33M
1 W Prestazione:
-3.61%
1M Prestazione:
-6.98%
6M Prestazione:
-35.31%
1 anno Prestazione:
-83.70%
Intervallo 1D:
$2.34
$2.5699
Intervallo di 1 settimana:
$2.29
$2.5699
Portata 52W:
$2.215
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Nome
Jasper Therapeutics Inc
Settore
Industria
Telefono
(650) 549-1400
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Confronta JSPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
2.40 | 69.53M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-08 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-09-09 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-08 | Iniziato | BTIG Research | Buy |
| 2024-06-27 | Iniziato | Stifel | Buy |
| 2024-05-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-03 | Iniziato | Evercore ISI | Outperform |
| 2024-03-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-18 | Iniziato | TD Cowen | Outperform |
| 2023-08-11 | Iniziato | CapitalOne | Overweight |
| 2022-02-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Credit Suisse | Outperform |
| 2021-10-21 | Iniziato | William Blair | Outperform |
| 2021-10-20 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-13 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - GlobeNewswire
JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors of Jasper, KBR, Spirit Aviation, and Molina to Contact the Firm About their Rights in Filed Class Action Lawsuits - GlobeNewswire
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FinancialContent
Portnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. Investors - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
What analysts say about Jasper Therapeutics Inc Equity Warrant stockCup and Handle Formations & Rapid Capital Trading Tips - earlytimes.in
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain OfficersJSPR - PR Newswire
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices - GlobeNewswire
JSPR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - GlobeNewswire
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Eastern Progress
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit - Your Wyoming Link
Bragar Eagel & Squire, P.C. Reminds Investors of Jasper, - GlobeNewswire
Important Notice to Long-Term Shareholders of Humana Inc. - GlobeNewswire
Jasper Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsJSPR - MarketScreener
Robbins LLP Reminds Jasper Therapeutics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against JSPR - Eastern Progress
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Jasper - GlobeNewswire
Inside INdiana Business - FinancialContent
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Hav - GuruFocus
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Jasper - GlobeNewswire
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
About Us - FinancialContent
JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) - GlobeNewswire
Oklahoma City NewsThe Oklahoman - FinancialContent
Upcoming Events - FinancialContent
JSPR Stockholders With Large Losses Should Contact Robbins LLP For Information About The Jasper Therapeutics, Inc. Securities Fraud Class Action - ACCESS Newswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Deadline Approaching: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - MarketScreener
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
Press Telegram - FinancialContent
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders To Inquire About Securities Fraud Class Action - MarketScreener
JSPR Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MarketScreener
Faruqi & Faruqi Reminds Jasper Investors of the Pending - GlobeNewswire
Jasper Therapeutics CEO Martell buys $99,630 in shares By Investing.com - Investing.com Australia
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Jasper Therapeutics prices $30M equity offering - MSN
Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Jasper Therapeutics Inc Azioni (JSPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lucas Svetlana | Director |
Sep 22 '25 |
Buy |
2.43 |
20,000 |
48,600 |
20,000 |
| MARTELL RON | President and CEO |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
74,118 |
| Shizuru Judith Anne | Director |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
156,901 |
| Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Option Exercise |
7.10 |
900 |
6,390 |
25,909 |
| Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Sale |
22.11 |
900 |
19,899 |
25,009 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):